Single-cell multiomic dissection of response and resistance to chimeric antigen receptor T cells against BCMA in relapsed multiple myeloma

被引:9
|
作者
Rade, Michael [1 ]
Grieb, Nora [2 ,3 ]
Weiss, Ronald [1 ,4 ]
Sia, Jaren [5 ]
Fischer, Luise [2 ]
Born, Patrick [2 ]
Boldt, Andreas [4 ]
Fricke, Stephan [4 ]
Franz, Paul [4 ]
Scolnick, Jonathan [5 ]
Venkatraman, Lakshmi [5 ]
Xu, Stacy [5 ]
Kloetzer, Christina [2 ]
Heyn, Simone [2 ]
Kubasch, Anne Sophie [2 ]
Baber, Ronny [6 ,7 ]
Wang, Song Yau [2 ]
Bach, Enrica [2 ]
Hoffmann, Sandra [2 ]
Ussmann, Jule [2 ]
Schetschorke, Birthe [2 ]
Hell, Saskia [2 ]
Schwind, Sebastian [2 ]
Metzeler, Klaus H. [2 ]
Herling, Marco [2 ]
Jentzsch, Madlen [2 ]
Franke, Georg-Nikolaus [2 ]
Sack, Ulrich [4 ]
Koehl, Ulrike [1 ,4 ]
Platzbecker, Uwe [2 ]
Reiche, Kristin [1 ,4 ,8 ]
Vucinic, Vladan [2 ]
Merz, Maximilian [2 ]
机构
[1] Fraunhofer Inst Cell Therapy & Immunol IZI, Leipzig, Germany
[2] Univ Hosp Leipzig, Dept Hematol Cellular Therapy & Hemostaseol, Leipzig, Germany
[3] Univ Hosp Leipzig, Innovat Ctr Comp Assisted Surg, Leipzig, Germany
[4] Univ Hosp Leipzig, Inst Clin Immunol, Leipzig, Germany
[5] Singleron Biotechnol, Cologne, Germany
[6] Univ Hosp Leipzig, Inst Lab Med Clin Chem & Mol Diagnost, Leipzig, Germany
[7] Univ Leipzig, Leipzig Med Biobank, Leipzig, Germany
[8] Ctr Scalable Data Analyt & Artificial Intelligence, Leipzig, Germany
关键词
THERAPY;
D O I
10.1038/s43018-024-00763-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Markers that predict response and resistance to chimeric antigen receptor (CAR) T cells in relapsed/refractory multiple myeloma are currently missing. We subjected mononuclear cells isolated from peripheral blood and bone marrow before and after the application of approved B cell maturation antigen-directed CAR T cells to single-cell multiomic analyses to identify markers associated with resistance and early relapse. Differences between responders and nonresponders were identified at the time of leukapheresis. Nonresponders showed an immunosuppressive microenvironment characterized by increased numbers of monocytes expressing the immune checkpoint molecule CD39 and suppressed CD8+ T cell and natural killer cell function. Analysis of CAR T cells showed cytotoxic and exhausted phenotypes in hyperexpanded clones compared to low/intermediate expanded clones. We identified potential immunotherapy targets on CAR T cells, like PD1, to improve their functionality and durability. Our work provides evidence that an immunosuppressive microenvironment causes resistance to CAR T cell therapies in multiple myeloma. Merz and colleagues perform single-cell multiomic analysis of mononuclear cells isolated from individuals receiving BCMA-directed CAR T cell therapy for myeloma and show that nonresponders are characterized by an immune-suppressive microenvironment.
引用
收藏
页码:1318 / 1333
页数:29
相关论文
共 50 条
  • [21] Multimodal dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin's lymphoma
    Gottschlich, A.
    Gruenmeier, R.
    Kavaka, V
    Mueller, P. J.
    Jobst, J.
    Thomas, M.
    Igl, V
    Briukhovetska, D.
    Simnica, D.
    Lorenzini, T.
    Maerkl, F.
    Oener, A.
    Brabenec, R.
    Nandi, S.
    Carlini, E.
    Tsiverioti, C.
    Stock, S.
    Michaelides, S.
    Jeremias, I
    Rosenwald, A.
    Marr, C.
    Beltran, E.
    Endres, S.
    Kobold, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 102 - 102
  • [22] Chimeric antigen receptor T cell therapy for multiple myeloma
    Hasegawa, Kana
    Hosen, Naoki
    INFLAMMATION AND REGENERATION, 2019, 39 (1)
  • [23] Chimeric antigen receptor T cell therapies for multiple myeloma
    Chao Wu
    Lina Zhang
    Qierra R. Brockman
    Fenghuang Zhan
    Lijuan Chen
    Journal of Hematology & Oncology, 12
  • [24] PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Zhang, W.
    Zhao, W.
    Liu, J.
    He, A.
    Chen, Y.
    Cao, X.
    Yang, N.
    Wang, B.
    Zhang, P.
    Zhang, Y.
    Wang, F.
    Lei, B.
    Gu, L.
    Yang, Y.
    Bai, J.
    Zhang, R.
    Wang, X.
    Ma, X.
    Wang, J.
    Wang, J.
    Wei, L.
    Zhang, J.
    Zang, X.
    Zhuang, Q.
    Fan, F. X.
    HAEMATOLOGICA, 2017, 102 : 2 - 3
  • [25] Effective Treatment of Relapsed/Refractory Multiple Myeloma Including Extramedullary Involvement By BCMA-Specific Chimeric Antigen Receptor-Modified T Cells
    Mi, Jian-Qing
    Fan, Xiaohu
    Xu, Jie
    Liu, Yuanfang
    Zhuang, Yan
    Yang, Shuangshuang
    Zhang, Wu
    Chen, Bing
    Wang, Yueying
    Weng, Xiangqin
    Li, Junmin
    Fu, Weijun
    Jiang, Hua
    Zhu, Li
    Chen, Zhu
    Chen, Sai-Juan
    Hou, Jian
    BLOOD, 2017, 130
  • [26] Treatment of relapsed or refractory multiple myeloma with bb2121 chimeric antigen receptor T cells
    Stocker, Nicolas
    HEMATOLOGIE, 2021, 27 (02): : 46 - 47
  • [27] Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma
    Huang, He
    uW, Heng-wei
    Hu, Yong-xian
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2020, 21 (01): : 29 - 41
  • [28] Cardiovascular events during treatment with anti-BCMA chimeric antigen receptor T-cells in multiple myeloma
    Mathilde, Chanut
    HEMATOLOGIE, 2023, 29 (05): : 274 - 275
  • [29] Safety and Efficacy of B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) with Cyclophosphamide Conditioning for Refractory Multiple Myeloma (MM)
    Cohen, Adam D.
    Garfall, Alfred L.
    Stadtmauer, Edward A.
    Lacey, Simon F.
    Lancaster, Eric
    Vogl, Dan T.
    Weiss, Brendan M.
    Ambrose, David E.
    Nelson, Anne Marie
    Chen, Fang
    Plesa, Gabriela
    Kulikovskaya, Irina
    Gonzalez, Vanessa
    Gupta, Minnal
    Young, Regina M.
    Dengel, Karen
    O'keefe, Laura
    Le, Samantha
    Richardson, Celeste
    Isaacs, Randi E.
    Melenhorst, J. Joseph
    Levine, Bruce L.
    June, Carl H.
    Milone, Michael C.
    BLOOD, 2017, 130
  • [30] Population Pharmacokinetics of Orvacabtagene Autoleucel, an Autologous BCMA-Directed Chimeric Antigen Receptor T-cell Product, in Patients with Relapsed/Refractory Multiple Myeloma
    Hu, Hongxiang
    Li, Yan
    Piasecki, Julia
    Hosseyni, Daniela
    Yan, Zhicheng
    Liu, Xianghong
    Ogasawara, Ken
    Zhou, Simon
    Cheng, Yiming
    CLINICAL CANCER RESEARCH, 2025, 31 (06) : 1163 - 1171